SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Isaacson PG, Piris MA, Catovsky D, et al. Splenic marginal zone lymphoma. In: JaffeES HN, SteinH, WardimanJW, editors. Tumors of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumors. Lyon: IARC Press, 2001: 135137.
  • 2
    Franco V, Florena AM, Iannitto E. Splenic marginal zone lymphoma. Blood. 2003; 101: 24642472.
  • 3
    Melo JV, Robinson DS, Gregory C, Catovsky D. Splenic B cell lymphoma with “villous” lymphocytes in the peripheral blood: a disorder distinct from hairy cell leukemia. Leukemia. 1987; 1: 294298.
  • 4
    Catovsky D, Matutes E. Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma. Semin Hematol. 1999; 36: 148154.
  • 5
    Isaacson PG, Matutes E, Burke M, Catovsky D. The histopathology of splenic lymphoma with villous lymphocytes. Blood. 1994; 84: 38283834.
  • 6
    Berger F, Felman P, Thieblemont C, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood. 2000; 95: 19501956.
  • 7
    Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87: 49904997.
  • 8
    Chacon JI, Mollejo M, Munoz E, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood. 2002; 100: 16481654.
  • 9
    Troussard X, Valensi F, Duchayne E, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d'Hematologie Cellulaire. Br J Haematol. 1996; 93: 731736.
  • 10
    Thieblemont C, Felman P, Berger F, et al. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma. 2002; 3: 4147.
  • 11
    Mulligan SP, Matutes E, Dearden C, Catovsky D. Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases. Br J Haematol. 1991; 78: 206209.
  • 12
    Camacho FI, Mollejo M, Mateo MS, et al. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases. Am J Surg Pathol. 2001; 25: 12681276.
  • 13
    Iannitto E, Ambrosetti A, Ammatuna E, et al. Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients. Cancer. 2004; 101: 20502057.
  • 14
    Bolam S, Orchard J, Oscier D. Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes. Br J Haematol. 1997; 99: 158161.
  • 15
    Lefrere F, Levy V, Francois S, et al. Fludarabine therapy in patients with splenic lymphoma with villous lymphocytes: an update. Leukemia. 2004; 18: 19241925.
  • 16
    Yasukawa M, Yamauchi H, Azuma T, Takada K, Ishimura M, Fujita S. Dramatic efficacy of fludarabine in the treatment of an aggressive case of splenic lymphoma with villous lymphocytes. Eur J Haematol. 2002; 69: 112114.
  • 17
    Lefrere F, Hermine O, Francois S, et al. Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma. 2000; 40: 113117.
  • 18
    Iannitto E, Minardi V, Calvaruso G, et al. Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes. Eur J Haematol. 2005; 75: 130135.
  • 19
    Bennett M, Sharma K, Yegena S, Gavish I, Dave HP, Schechter GP. Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica. 2005; 90: 856858.
  • 20
    Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin Oncol. 2002; 29: 1822.
  • 21
    Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004; 104: 30643071.
  • 22
    Zinzani PL, Pulsoni A, Perrotti A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol. 2004; 22: 26542661.
  • 23
    McLaughlin P, Hagemeister FB, Rodriguez MA, et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of Stage IV indolent lymphoma. Semin Oncol. 2000; 27: 3741.
  • 24
    Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005; 23: 40794088.
  • 25
    Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994; 8: 16401645.
  • 26
    Huh YO, Keating MJ, Saffer HL, Jilani I, Lerner S, Albitar M. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am J Clin Pathol. 2001; 116: 437443.
  • 27
    Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored International Working Group. J Clin Oncol. 1999; 17: 12441253.
  • 28
    Parry-Jones N, Matutes E, Gruszka-Westwood AM, Swansbury GJ, Wotherspoon AC, Catovsky D. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol. 2003; 120: 759764.
  • 29
    Arcaini L, Orlandi E, Scotti M, et al. Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. Clin Lymphoma. 2004; 4: 250252.
  • 30
    Ruiz-Ballesteros E, Mollejo M, Rodriguez A, et al. Splenic marginal zone lymphoma. Proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood. 2005; 106: 18311838.
  • 31
    Iannitto E, Ammatuna E, Florena AM, Franco V. Prognostic features of splenic lymphoma with villous lymphocytes. Br J Haematol. 2003; 123: 370371.
  • 32
    Cro L, Guffanti A, Colombi M, et al. Diagnostic role and prognostic significance of a simplified immunophenotypic classification of mature B cell chronic lymphoid leukemias. Leukemia. 2003; 17: 125132.
  • 33
    Levy M, Copie-Bergman C, Gameiro C, et al. Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol. 2005; 23: 50615066.
  • 34
    Gruszka-Westwood AM, Hamoudi RA, Matutes E, Tuset E, Catovsky D. p53 Abnormalities in splenic lymphoma with villous lymphocytes. Blood. 2001; 97: 35523558.
  • 35
    Baldini L, Fracchiolla NS, Cro LM, et al. Frequent p53 gene involvement in splenic B-cell leukemia/lymphomas of possible marginal zone origin. Blood. 1994; 84: 270278.
  • 36
    Traverse-Glehen A, Davi F, Ben Simon E, et al. Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection. Haematologica. 2005; 90: 470478.
  • 37
    Dewolf Peeters C. Analysis of VH genes in 49 marginal zone lymphoma cases reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection [abstract]. Haematologica. 2005; 90: 435.